Faricimab▼ in neovascular age-related macular degeneration (nAMD): efficacy, safety, and durability through week 48 in the phase 3 TENAYA and LUCERNE trials
This presentation reports the pooled week 48 primary results, including the proportion of patients with an absence of retinal fluid through week 12, from the phase 3 TENAYA and LUCERNE trials of faricimab▼, a bispecific antibody that independently binds and neutralizes Ang-2 and VEGF-A, in patients with neovascular age-related macular degeneration. TENAYA and LUCERNE investigated the efficacy, safety, and durability of faricimab▼, administered at individualized treatment intervals of up to every 16 weeks compared with aflibercept administered every 8 weeks.